Related Experiment Video

Updated: Dec 31, 2025

A Murine Model of Fetal Exposure to Maternal Inflammation to Study the Effects of Acute Chorioamnionitis on Newborn Intestinal Development
08:50

A Murine Model of Fetal Exposure to Maternal Inflammation to Study the Effects of Acute Chorioamnionitis on Newborn Intestinal Development

Published on: June 24, 2020

4.2K

Liver Diseases in the Perinatal Period: Interactions Between Mother and Infant

Samar H Ibrahim1, Maureen M Jonas2, Sarah A Taylor3

  • 1Division of Pediatric Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.

Hepatology (Baltimore, Md.)
|January 12, 2020
PubMed

Insights

This review covers perinatal liver diseases in mothers and infants, focusing on neonatal acute liver failure, gestational alloimmune liver disease, and viral hepatitis transmission. It also examines maternal obesity

Area of Science:

  • Perinatal Medicine
  • Hepatology
  • Neonatology

Background:

  • Liver diseases in the mother-infant dyad can manifest from 20 weeks gestation to 28 days postpartum.
  • Existing literature lacks a comprehensive overview of diverse perinatal liver conditions and their management.

Purpose of the Study:

  • To review current diagnostic and management strategies for neonatal acute liver failure.
  • To discuss advancements in diagnosing and managing gestational alloimmune liver disease.
  • To explore the implications of viral hepatitis transmission and emerging concepts in maternal health impacting offspring liver conditions.

Main Methods:

  • Literature review focusing on perinatal liver diseases.
  • Synthesis of current approaches to neonatal acute liver failure.
  • Analysis of diagnostic and management progress in gestational alloimmune liver disease and viral hepatitis.

Main Results:

  • Neonatal acute liver failure requires timely diagnosis and management.
  • Gestational alloimmune liver disease diagnosis and treatment have seen progress.
  • Maternal health factors like obesity and nutrition influence offspring's nonalcoholic steatohepatitis risk.

Conclusions:

  • Effective management of perinatal liver diseases requires a multidisciplinary approach.
  • Understanding mother-to-child transmission of viral hepatitis is crucial for public health.
  • Further research into maternal factors influencing fetal liver health is warranted.

More Related Videos

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

11.7K
A Common Marmoset Model of Mother-Infant Intervention for Breastfeeding Disorders in the Presence of Paternal Inhibition and Maternal Neglect05:04

A Common Marmoset Model of Mother-Infant Intervention for Breastfeeding Disorders in the Presence of Paternal Inhibition and Maternal Neglect

Published on: September 22, 2023

786

Related Concept Videos

Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
702
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
174
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
140
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
152
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
211
Transcytosis of IgG01:15

Transcytosis of IgG

Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
4.0K